Hydrogel News and Research

RSS

CeloNova BioSciences submits a request for approval of its new Embozene Microsphere

CeloNova BioSciences today announced that the company is submitting to its European Notified Body a request for approval of its new, lime green, 2800 micron size Embozene(TM) Microsphere.

31 Oct 2009

CryoLife reports a net income of $1.9 million for the third quarter of 2009

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today that revenues for the third quarter of 2009 increased 5 percent to a quarterly record of $28.2 million compared to $26.8 million for the third quarter of 2008.

29 Oct 2009

CryoLife granted FDA approval for BioFoam human clinical trial

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company's Investigational Device Exemption (IDE) to conduct a human clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology.

27 Oct 2009

Assets of Cartilix acquired by Biomet

Biomet, Inc., a global leader in the manufacture of orthopedic and dental medical devices, announced today its acquisition of the assets of Cartilix, a Foster City, CA based company that has developed proprietary cartilage repair technology.

21 Oct 2009

New 3D scaffolding technology may help grow skin and blood vessels in labs

Scientists are developing new scaffolding technology which could be used to grow tissues such as skin, nerves and cartilage using 3D spaghetti-like structures. Their research is highlighted in the latest issue of Business, the quarterly highlights magazine of the Biotechnology and Biological Sciences Research Council (BBSRC).

19 Oct 2009

CeloNova BioSciences' Embozene Microspheres receives approval

CeloNova BioSciences, Inc. has received approval from its European regulatory body, the British Standards Institution, to expand the list of medical indications for which Embozene(TM) Microspheres may be used and to add a tenth size of the product.

14 Oct 2009

HyperBranch Medical Technology's NuSeal 30 hernia mesh fixation sealant product receives CE Mark

HyperBranch Medical Technology, Inc. announced today that it has received a CE Mark for its NuSeal 30 hernia mesh fixation sealant product. NuSeal 30 is used in hernia procedures to adhere the mesh. NuSeal 30 provides for secure mesh placement, minimizes pain caused by other fixation devices and gradually degrades as the body heals.

13 Oct 2009

Systagenix Wound Management forms new global Medical Advisory Board

Systagenix Wound Management has announced the formation of a new global Medical Advisory Board, consisting of a group of multi-disciplinary and highly respected wound care clinicians and practitioners from North America and Europe, which will be led by Systagenix's newly appointed Medical Director, Dr Robert Snyder.

13 Oct 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.

13 Oct 2009

New embolization technique offers better clinical outcomes in the treatment of liver cancer

The authors of a newly published paper in the September/October journal Vascular Disease Management conclude that the micro-bland embolization technique possible with Embozene(TM) Color-Advanced Microspheres leads to better clinical outcomes.

6 Oct 2009

ARRA stimulus funds fuel research projects across America

The Association of American Universities (AAU), the Association of Public and Land-grant Universities (APLU), and The Science Coalition (TSC) today released highlighted examples of the important scientific work happening across the country as a result of the American Recovery and Reinvestment Act of 2009 (ARRA). The brief report summarizes just a handful of the thousands of projects benefiting from stimulus dollars.

30 Sep 2009

Oculus launches Microcyn Skin & Wound HydroGel OTC

Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.

29 Sep 2009

Biomaterial gel for treating spinal cord injury

Research led by a scientist at the Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has shown injecting biomaterial gel into a spinal cord injury site provides significantly improved healing.

18 Sep 2009

Six research project grants aimed at improving human health awarded

Six research project grant awards totaling $5.1 million will be made to Washington life sciences organizations and their partners, the state’s Life Sciences Discovery Fund announced today.

16 Sep 2009

New hydrogel mats extends anti-infection protection

Treatment of hospital-related infections in the U.S. costs up to $11 billion a year and about half of those infections are related to medical devices implanted in patients. Until now, efforts to control drug-resistant biofilms on such devices have been largely unsuccessful.

15 Sep 2009

Oculus Innovative Sciences Receives Medicare HCPCS Code For Reimbursement Of Microcyn® Skin & Wound Hydrogel

Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, announced today that Noridian Administrative Services LLC, which is the pricing, data analysis and coding contractor for the Medicare program with respect to durable medical equipment, prosthetics, orthotics, and medical supplies, has assigned a Medicare HCPCS code for Oculus’ recently introduced Microcyn Skin & Wound HydroGel.

11 Sep 2009

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

Asset Purchase Agreement Signed for Marketed Prescription Products Desonate(R) and NeoBenz(R) Micro

3 Sep 2009

USPTO awards two new patents to Nerites

Nerites Corporation announced Thursday that the United States Patent and Trademark Office (USPTO) issued two new patents covering the company’s technology. These “composition of matter” patents provide underlying intellectual property protection for surgical adhesives, films, and coatings. Nerites’ scientists create synthetic mimetics of the protein components used by marine mussels to stick to rocks under water.

28 Aug 2009

Sigma-Aldrich offers customizable synthetic extracellular matrix (ECM) for stem cell research

Sigma-Aldrich (Nasdaq: SIAL) today announced an agreement with Glycosan BioSystems for the sale of HyStem(TM), a fully customizable synthetic extracellular matrix (ECM) for stem cell research. HyStem offers researchers flexibility to tailor microenvironments for their cultured cells that mimic natural in vivo conditions, optimizing stem cell proliferation and differentiation. HyStem was developed by Glycosan BioSystems and will be sold by Sigma-Aldrich under a non-exclusive distribution agreement.

13 Aug 2009

New bio-hybrid materials could be used as sensors, catalysts, drug-delivery systems, more

Bacteria play a role in myriad industrial processes from fermentation to cleaning up environmental pollution. But floating freely in solution, the microbial cells constantly multiply, generating biomass that must be removed periodically, causing downtime. Additionally, the microorganisms cannot be localized to a specific region of interest.

3 Aug 2009

Hydrogel News and Research

CeloNova BioSciences submits a request for approval of its new Embozene Microsphere

CryoLife reports a net income of $1.9 million for the third quarter of 2009

CryoLife granted FDA approval for BioFoam human clinical trial

Assets of Cartilix acquired by Biomet

New 3D scaffolding technology may help grow skin and blood vessels in labs

CeloNova BioSciences' Embozene Microspheres receives approval

HyperBranch Medical Technology's NuSeal 30 hernia mesh fixation sealant product receives CE Mark

Systagenix Wound Management forms new global Medical Advisory Board

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

New embolization technique offers better clinical outcomes in the treatment of liver cancer

ARRA stimulus funds fuel research projects across America

Oculus launches Microcyn Skin & Wound HydroGel OTC

Biomaterial gel for treating spinal cord injury

Six research project grants aimed at improving human health awarded

New hydrogel mats extends anti-infection protection

Oculus Innovative Sciences Receives Medicare HCPCS Code For Reimbursement Of Microcyn® Skin & Wound Hydrogel

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

USPTO awards two new patents to Nerites

Sigma-Aldrich offers customizable synthetic extracellular matrix (ECM) for stem cell research

New bio-hybrid materials could be used as sensors, catalysts, drug-delivery systems, more

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News